Abstracts tagged "longitudinal studies"

Abstract Number: 2712 • 2018 ACR/ARHP Annual Meeting
Evaluation of Longitudinal Outcomes in Scleroderma Patients with Negative Immunofluorescent Anti-Nuclear Antibodies
Mayce Haj-Ali¹, Derek Jones², Sean McNish³, Sarah Stupp³, Marissa Mangini³ and Victoria Shanmugam⁴, ¹Department of Medicince, The George Washington University School of Medicine and Health Sciences, Washington, DC, ²The George Washington University, Washington, DC, ³The George Washington University School of Medicine and Health Sciences, Washington, DC, ⁴Rheumatology, The George Washington University, Washington, DC
Background/Purpose: Systemic Sclerosis (SSc) is an autoimmune disease characterized by inflammation, fibrosis, and vasculopathy. Historical data indicates approximately 90% of patients with SSc test positive…
Abstract Number: 2882 • 2018 ACR/ARHP Annual Meeting
Minimal Progression of Disease Manifestation in Patients with Sjögren’s Syndrome Re-Evaluated Multiple Years after Initial Disease Classification
Astrid Rasmussen¹, Lida Radfar², Kimberly Hefner³, David M. Lewis⁴, C. Erick Kaufman⁵, Donald U. Stone⁶, Kerry M. Leehan¹, Kiely Grundahl⁷, Christopher J. Lessard¹, A. Darise Farris⁸, R. Hal Scofield⁹ and Kathy L. Sivils¹⁰, ¹Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Department of Oral Diagnosis and Radiology, University of Oklahoma College of Dentistry, Oklahoma City, OK, ³Hefner Eye Care Center, Oklahoma City, OK, ⁴Department of Oral and Maxillofacial Pathology, University of Oklahoma College of Dentistry, Oklahoma City, OK, ⁵Medicine, University of Oklahoam Health Sciences Center, Oklahoma City, OK, ⁶Ophthalmology, Johns Hopkins University, Baltimore, MD, ⁷Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma CIty, OK, ⁸Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁹Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ¹⁰Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Classical connective tissue diseases, such as SLE and RA have well documented progression of disease and damage accrual. However, the natural history of Sjögren’s…
Abstract Number: 2966 • 2018 ACR/ARHP Annual Meeting
Ultrasound Shows Rapid Reduction of Uric Load during Treat-to-Target Approach in Gout Patients: Results from a Longitudinal Study
Hilde B Hammer¹, Lars Fritjof Karoliussen², Lene Terslev³, Espen A. Haavardsholm¹, Tore Kvien⁴ and Till Uhlig⁵, ¹Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Dept of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Rheumatology, Rigshospitalet Glostrup, Copenhagen, Denmark, ⁴RAID working group for EULAR, Zurich, Switzerland, ⁵Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose: Uric monosodium urate (MSU) depositions are detected by ultrasound (US), and US is included in the ACR/EULAR classification criteria for gout. OMERACT definitions for…
Abstract Number: 2946 • 2017 ACR/ARHP Annual Meeting
Identifying Rapid Structural Disease Progression in Knee Osteoarthritis
Jamie E. Collins^1,2, Jeffrey N. Katz^2,3 and Elena Losina^1,2, ¹Orthopaedic and Arthritis Center for Outcomes Research, Department of Orthopedic Surgery, Brigham & Women's Hospital, Boston, MA, ²Harvard Medical School, Boston, MA, ³Rheumatology, Immunology, and Allergy, Brigham & Women's Hospital, Boston, MA
Background/Purpose: Knee OA is a heterogeneous disease, with some patients experiencing rapid deterioration and others experiencing slow disease progression. Identifying patients likely to experience rapid…
Abstract Number: 330 • 2017 ACR/ARHP Annual Meeting
Change in Bone Mineral Density in Patients with Rheumatoid Arthritis: Minimal 10-Year Follow-up
Hiraku Motomura, Isao Matsushita, Toshihito Hiraiwa and Tomoatsu Kimura, Department of Orthopaedic Surgery, Faculty of Medicine, University of Toyama, Toyama, Japan
Background/Purpose: To investigate the long-term change in bone mineral density (BMD) in patients with rheumatoid arthritis (RA). Methods: In a longitudinal study of 40 patients…
Abstract Number: 2957 • 2017 ACR/ARHP Annual Meeting
Factors Associated with Cardiac Dysfunction in a Longitudinal Follow-up of Neonatal Lupus
Amit Saxena¹, Peter M. Izmirly², Rebecca Bomar², Shireen Golpanian², Deborah Friedman³ and Jill P. Buyon¹, ¹Rheumatology, New York University School of Medicine, New York, NY, ²New York University School of Medicine, New York, NY, ³New York Medical College, Valhalla, NY
Background/Purpose: There are minimal data and no longitudinal studies regarding the long term cardiac health of children with cardiac manifestations of neonatal lupus (NL). This…
Abstract Number: 715 • 2017 ACR/ARHP Annual Meeting
Long-Term Outcome of Demyelnating Syndrome in Systemic Lupus Erythematosus: A Longitudinal Study
Jamal A. Mikdashi¹ and Ipolia Ramadan², ¹Div of Rheumatology, Univ of Maryland Schl of Med, Baltimore, MD, ²National Institue of Health, Rockville, MD
Background/Purpose: Demyelinating syndromes (DS) in systemic lupus erythematosus (SLE) are characterized by inflammation, demyelination and neurodegeneration. Little is known, however, about the tenet of dissemination…
Abstract Number: 732 • 2017 ACR/ARHP Annual Meeting
Progression of Skin Fibrosis Is Associated with Decline in Lung Function in Patients with Diffuse Cutaneous Systemic Sclerosis: A European Scleroderma Trials and Research (EUSTAR) Analysis
Wanlong Wu¹, Suzana Jordan², Nicole Graf³, Janethe Pena⁴, John Curram⁵, Yannick Allanore⁶, Marco Matucci-Cerinic⁷, Janet E. Pope⁸, Christopher Denton⁹, Dinesh Khanna¹⁰ and Oliver Distler¹, ¹Department of Rheumatology, Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland, ²Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ³Graf Biostatistics, Winterthur, Switzerland, ⁴Bayer HealthCare Pharmaceuticals Inc, Whippany, NJ, ⁵Bayer Plc, Newbury, United Kingdom, ⁶Department of Rheumatology, Cochin Hospital, Paris Descartes University, Paris, France, ⁷Dept of Medicine/Div of Rheum, University of Florence, Florence, Italy, ⁸Department of Medicine, Division of Rheumatology, University of Western Ontario, St Joseph's Health Care, London, ON, Canada, ⁹Department of Rheumatology, University College London, Royal Free Hospital, London, United Kingdom, ¹⁰Division of Rheumatology, Department of Internal Medicine, Scleroderma Program, University of Michigan, Ann Arbor, MI
Background/Purpose: Previously, we have identified short disease duration (≤15 months) and low baseline modified Rodnan skin score (mRSS) (≤22/51) as independent predictors of progressive skin…
Abstract Number: 784 • 2017 ACR/ARHP Annual Meeting
Damage and Predictors of Damage in Takayasu’s Arteritis
Antoine G. Sreih¹, Tanaz A. Kermani², David Cuthbertson³, Simon Carette⁴, Nader A. Khalidi⁵, Curry L. Koening⁶, Carol A. Langford⁷, Carol A. McAlear⁸, Paul A. Monach⁹, Larry W. Moreland¹⁰, Christian Pagnoux¹¹, Philip Seo¹², Kenneth J. Warrington¹³, Steven R. Ytterberg¹³ and Peter A. Merkel^1,14, ¹Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Division of Rheumatology, University of California, Los Angeles, CA, ³Biostatistics and Informatics, Department of Pediatrics, University of South Florida, Tampa, FL, ⁴Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁵Rheumatology, McMaster University, Hamilton, ON, Canada, ⁶Rheumatology, University of Utah, Salt Lake City, UT, ⁷Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ⁸University of Pennsylvania, Philadelphia, PA, ⁹Boston University School of Medicine, Boston, MA, ¹⁰Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ¹¹Rheumatology-Vasculitis clinic, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ¹²Medicine, Johns Hopkins University, Baltimore, MD, ¹³Rheumatology, Mayo Clinic, Rochester, MN, ¹⁴Biostatistics, Epidemiology, and Bioinformatics, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Information regarding the degree and the predictors of damage in patients with Takayasu’s arteritis (TAK) is limited. This study aimed to characterize damage and…
Abstract Number: 943 • 2017 ACR/ARHP Annual Meeting
The Course of the Forced Vital Capacity during Treatment for Systemic Sclerosis-Related Interstitial Lung Disease Predicts Long-Term Survival in 2 Independent Cohorts
Elizabeth R. Volkmann¹, Donald P. Tashkin¹, Myung Sim¹, Dinesh Khanna², Michael Roth³, Philip J. Clements³, Daniel E. Furst¹, Lynette Keyes-Elstein⁴, Ashley Pinckney⁴, Ellen Goldmuntz⁵, Robert Elashoff⁶ and Keith Sullivan⁷, ¹University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ²University of Michigan, Ann Arbor, MI, ³Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁴Rho Federal Systems, Inc., Chapel Hill, NC, ⁵NIAID, NIH, Bethesda, MD, ⁶University of California, Los Angeles, Los Angeles, CA, ⁷Duke University, Durham, NC
Background/Purpose: While prior observational studies have identified predictors of mortality in systemic sclerosis-interstitial lung disease (SSc-ILD), no studies have evaluated predictors of long-term mortality in…
Abstract Number: 1248 • 2017 ACR/ARHP Annual Meeting
Evaluation of Validated Patient Reported Outcome Measures to Assess Sensitivity to Change in Patients with Systemic Sclerosis and Gastroesophageal Reflux Disease —a Scleroderma Clinical Trials Consortium Collaborative Project
Zsuzsanna McMahan¹, Tracy M. Frech², David Lim³, Veronica J. Berrocal⁴, Cosimo Bruni⁵, Marco Matucci-Cerinic⁶, Vanessa Smith⁷, Karin Melsons⁸, Susanna Proudman⁹, Jinyu Zhang¹⁰, Fabian A Mendoza¹¹, Melanie Woods³ and Dinesh Khanna³, ¹Department of Internal Medicine, Johns Hopkins University, Baltimore, MD, ²Division of Rheumatology, University of Utah, Salt Lake City, UT, ³University of Michigan, Ann Arbor, MI, ⁴Div of Rheumatology, University of Michigan, Ann Arbor, MI, ⁵Department of Experimental and Clinical Medicine, Division of Rheumatology, University of Florence, Firenze, Italy, ⁶Dept of Medicine/Div of Rheum, University of Florence, Firenze, Italy, ⁷Faculty of Internal Medicine, Ghent University, Ghent, Belgium, ⁸Ghent University, Gent, Belgium, ⁹Discipline of Medicine, University of Adelaide, Adelaide, Australia, ¹⁰Thomas Jefferson University, Philadelphia, PA, ¹¹Jefferson Institute of Molecular Medicine and Scleroderma Center, Rheumatology Division, Department of Medicine, Thomas Jefferson University, Philadelphia, PA
Background/Purpose: The UCLA SCTC GIT 2.0 and NIH PROMIS GI Symptoms Scales are validated in scleroderma to assess patient-reported gastrointestinal (GI) involvement. We sought to…
Abstract Number: 1277 • 2017 ACR/ARHP Annual Meeting
Longitudinal Predictors of Physical Function in Juvenile Myositis
Kaveh Ardalan^1,2, Hannah L. Palac^3,4, Julia (Jungwha) Lee⁴, Madison Wolfe^5,6, Gabrielle A. Morgan^7,8 and Lauren M. Pachman⁹, ¹Departments of Pediatrics and Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, ²Division of Rheumatology, Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, ³Abbvie, Inc, Chicago, IL, ⁴Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁵Division of Rheumatology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ⁶Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁷Cure JM Program of Excellence in Myositis Research, Chicago, IL, ⁸Rheumatology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ⁹Cure JM Program of Excellence in Juvenile Myositis Research, Stanley Manne Children’s Research Institute, affiliated with Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL
Background/Purpose: Juvenile myositis (JM) is marked by skin rashes, proximal muscle weakness, and deconditioning causing potentially severe disability. Studies examining long-term physical function in JM…
Abstract Number: 1500 • 2017 ACR/ARHP Annual Meeting
Longitudinal Analysis of Different Therapeutic Strategies in Patients with Primary Sjögren’s Syndrome
Kristen Davies¹, Kamran Mirza¹, Jessica Tarn², Marian Regan³, Saravanan Vadivelu⁴, Gavin Clunie⁵, Jacqueline Andrews⁶, Elizabeth Price⁷, Steve Young-Min⁸, Ian Giles⁹, Bhaskar Dasgupta¹⁰, Cathy Lawson¹¹, Nagui Gendi¹², Neil J. McHugh¹³, Michele Bombardieri¹⁴, Costantino Pitzalis¹⁴, Nurhan Sutcliffe¹⁴, Simon Bowman¹⁵, Dennis Lendrem^16,17 and Wan-Fai Ng^2,18, ¹Institute of Cellular Medicine, Musculoskeletal Research Group, Institute of Cellular Medicine, Newcastle University, Newcastle-Upon-Tyne, UK, Newcastle-Upon-Tyne, United Kingdom, ²Musculoskeletal Research Group, Institute of Cellular Medicine, Newcastle University, Newcastle-Upon-Tyne, UK, Newcastle-Upon-Tyne, United Kingdom, ³Royal Derby Hospital, Derby, UK, Derby, United Kingdom, ⁴Queen Elizabeth Hospital, Gateshead, UK, Gateshead, United Kingdom, ⁵Ipswich Hospital NHS Trust, Ipswich, UK, Ipswich, United Kingdom, ⁶Leeds Teaching Hospitals NHS Trust, Leeds, UK, Leeds, United Kingdom, ⁷Great Western Hospital, Swindon, UK, Swindon, United Kingdom, ⁸Queen Alexander Hospital, Portsmouth, UK, Portsmouth, United Kingdom, ⁹Centre for Rheumatology, University College London, Centre for Rheumatology, University College London, UK, London, United Kingdom, ¹⁰Rheumatology, Southend University Hospital NHS Foundation Trust, Southend, UK, Westcliff-on-Sea, United Kingdom, ¹¹Harrogate District Hospital, Harrogate, UK, Harrogate, United Kingdom, ¹²Basildon and Thurrock University Hospital, Basildon, UK, Basildon, United Kingdom, ¹³Royal National Hospital for Rheumatic Diseases, Bath, UK, Bath, United Kingdom, ¹⁴Barts Health NHS Trust & Barts and the London School of Medicine & Dentistry, London, UK, London, United Kingdom, ¹⁵Department of Rheumatology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK, Birmingham, United Kingdom, ¹⁶Musculoskeletal Research Group, Institute of Cellular Medicine, Newcastle University, Newcastle-Upon-Tyne, UK, Newcastle-upon-Tyne, United Kingdom, ¹⁷Newcastle-upon-Tyne Hospitals NHS Foundation Trust, Newcastle-upon-Tyne, UK, Newcastle, United Kingdom, ¹⁸Newcastle-upon-Tyne Hospitals NHS Foundation Trust, Newcastle-upon-Tyne, UK, Newcastle-Upon-Tyne, United Kingdom
Background/Purpose: Primary Sjögren’s syndrome (pSS) is a systemic autoimmune rheumatic disease characterised by sicca features and systemic manifestations such as pain and fatigue. The classic…
Abstract Number: 1613 • 2017 ACR/ARHP Annual Meeting
Natural History of Disease Activity and Damage in Patients with Cutaneous Lupus Erythematosus on Standard of Care Treatments Using Longitudinal Registries from Two Academic Dermatology Centers
Noelle M. Teske¹, Khor Jia Ker^2,3, Rui Feng⁴, Benjamin F. Chong¹ and Victoria P Werth⁵, ¹Dermatology, University of Texas Southwestern Medical Center, Dallas, TX, ²Dermatology, National Skin Centre, Singapore, Singapore, ³Dermatology, University of Pennsylvania, Philadelphia, PA, ⁴Department of Biostatistics and Epidemiology at the Hospital of the University of Pennsylvania, Philadelphia, PA, ⁵University of Pennsylvania and the VA Medical Center, Philadelphia, PA
Background/Purpose: The natural disease course of patients with cutaneous lupus erythematosus (CLE) on standard-of-care treatments is not fully characterized. We sought to characterize their disease…
Abstract Number: 1642 • 2017 ACR/ARHP Annual Meeting
Role of Plaque in Predicting Cardiovascular Events in Women with Lupus over a 20 Year Followup
Erika Joyce¹, Linda Santelices², Jennifer Mall², Kristy Huysman², Amy Xiaoqin Tang³, Michael Anderson², Jennifer Elliott⁴, Amy H. Kao^5,6 and Susan Manzi², ¹Internal Medicine, Allegheny Health Network, Pittsburgh, PA, ²Medicine, Allegheny Health Network, Pittsburgh, PA, ³Lupus Center of Excellence, Allegheny Health Network Research Institute, Pittsburgh, PA, ⁴Allegheny Health Network, Pittsburgh, PA, ⁵EMD Serono Research & Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), Billerica, MA, ⁶EMD Serono Research & Development Institute, Inc. (a business of Merck KGaA), Billerica, MA
Background/Purpose: The increased risk of premature cardiovascular disease (CVD) in systemic lupus erythematosus (SLE) patients has been well reported. Multiple series have demonstrated a higher…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].